Navigation Links
Alzheimer's Drug Development Summit: CBI to Donate Portion of This Week's Proceeds to the Alzheimer's Association
Date:9/21/2009

WOBURN, Mass., Sept. 21 /PRNewswire/ -- The Center for Business Intelligence (CBI) announced today that they will donate a portion of the proceeds from their Alzheimer's Drug Development Summit to the Alzheimer's Association. CBI will donate $100 for every registration completed this week, September 21-25, 2009, in recognition of World Alzheimer's Day.

World Alzheimer's Day joins Alzheimer's associations, globally, to raise awareness and encourage citizens to take action against the disease. CBI is committed to developing forums that unite industry thought leaders in the field of Alzheimer's research and drug development. "By putting together cutting-edge forums and supporting the Alzheimer's Association, we're proud to be doing our part on this very important day," said Michelle DeMunbrun, Program Manager at CBI. "Every little bit counts, and with all of our collective efforts, it's only a matter of time before we establish a cure for this devastating disease."

The annual Alzheimer's Summit, in its third year, will be chaired by Ronald Black, M.D., Assistant Vice President, Neuroscience, Wyeth. The conference will take place in Arlington, VA, on December 8-9, 2009. Day-two case study, "Addressing the Two Most Challenging Aspects of Alzheimer's Clinical Trials -- Accelerating Patient Recruitment and Reducing Drop-Out Rates" will be a highlight at this timely and pertinent event. In addition to five other case studies and an extended panel discussion, attendees will have multiple opportunities to network with industry colleagues.

Top neuroscience and drug development executives from companies such as Eisai, Alzheimer's Association, The Critical Path Institute, Elan Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Wyeth and The National Institute on Aging will explore how to:

  • Examine targeting protein kinases and the unique challenges associated with CNS drug discovery
  • Discuss whether disease modifying therapeutics can show symptomatic benefits
  • Assess whether the AD drug candidates, to date, failed the clinical trials or the clinical trials failed the drugs
  • Gain a better understanding of AB trafficking and the peripheral sink hypothesis
  • Learn the potential role of MRI and PET imaging in biomarkers in facilitating Alzheimer's disease drug development
  • Examine the implications of ADNI data for use of neuroimaging and fluid biomarkers in clinical trials for Alzheimer's disease
  • Discuss the integration of a mobile clinical network into an Alzheimer's clinical trial to meet sponsor and investigator deliverables and objectives

The conference brings together key researchers and stakeholders to examine the latest symptomatic and disease modifying approaches for the clinical development of new AD therapies. For more information on the conference or to view the agenda, please visit http://www.cbinet.com/alzheimers.

About CBI:

A subsidiary of Advanstar Communications, The Center for Business Intelligence is dedicated to developing market-driven, unbiased conferences in the pharmaceutical, biotechnology, and medical device industries. For more information, please visit http://www.cbinet.com.

For additional information or media inquiries, please contact: Emily Forest, Marketing Manager, at 339-298-2156.

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE The Center for Business Intelligence
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Allegiance Equity Corporation announces collaboration with Canadian Dairy Commission and Guelph Food Technologies Corporation for Alzheimers and Dementia formulation GG-XT
2. Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Global Experts Explore Entire Spectrum of Aids Vaccine Development
8. Vical Names Andrew de Guttadauro Vice President, Corporate Development
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. SemBioSys updates Apo AI development program
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Palo Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... is set to take place on 7th and 8th June 2018 in San Francisco, ... and policy influencers as well as several distinguished CEOs, board directors and government officials ...
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Rotary Club. The event entitled “Stem Cells and Their Regenerative Powers,” ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
Breaking Biology News(10 mins):